ATLANTA, GA – – (Newsfile Corp. – October 4, 2021) – – Holzer & Holzer, LLC is investigating whether Owlet, Inc. (“OWLT or the “Company”) (NYSE: OWLT) complied with federal securities laws. On October 4, 2021, the Company disclosed through an SEC filing that it received a warning letter from the FDA. The FDA’s letter informed Owlet that the Company’s marketing for its Owlet Smart Sock in the United States “renders the Smart Sock a medical device requiring premarket clearance or approval from FDA, and that the Company has not obtained such clearance or approval in violation of the Federal, Food, Drug, and Cosmetic Act.” The FDA has requested that the Company take “prompt action” to remedy the alleged violations. On this report, the price of the Company’s stock plummeted. If you purchased Owlet stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.